Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tetrabenazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A2 known ✓ | Q05940 | 7/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | POLB | P06746 | 1/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | HPGD | P15428 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | SCN1A | P35498 | 1/20 | 1.00 |
| ▸ | HTR2B | P41595 | 1/20 | 1.00 |
| ▸ | MTOR | P42345 | 1/20 | 1.00 |
| ▸ | SCN2A | Q99250 | 1/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 1.00 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tetrabenazine SCHEMBL12394431 | 1.00 | SLC18A2 (1.00) | SLC18A2KDM4EABCB11ALDH1A1POLB | |
| Tetrabenazine SCHEMBL13401094 | 1.00 | SLC18A2 (1.00) | SLC18A2KDM4EABCB11ALDH1A1POLB | |
| Tetrabenazine SCHEMBL62026 | 1.00 | SLC18A2 (1.00) | SLC18A2KDM4EABCB11ALDH1A1POLB | |
| Tetrabenazine SCHEMBL29609598 | 1.00 | SLC18A2 (1.00) | SLC18A2KDM4EABCB11ALDH1A1POLB | |
| Tetrabenazine SCHEMBL9971241 | 1.00 | SLC18A2 (1.00) | SLC18A2KDM4EABCB11ALDH1A1POLB | |
| Tetrabenazine SCHEMBL16992567 | 1.00 | SLC18A2 (1.00) | SLC18A2KDM4EABCB11ALDH1A1POLB | |
| Tetrabenazine SCHEMBL16992566 | 1.00 | SLC18A2 (1.00) | SLC18A2KDM4EABCB11ALDH1A1POLB | |
| Tetrabenazine SCHEMBL9971276 | 1.00 | SLC18A2 (1.00) | SLC18A2KDM4EABCB11ALDH1A1POLB | |
| Tetrabenazine SCHEMBL20049732 | 1.00 | SLC18A2 (1.00) | SLC18A2KDM4EABCB11ALDH1A1POLB | |
| Tetrabenazine SCHEMBL29380971 | 1.00 | SLC18A2 (1.00) | SLC18A2KDM4EABCB11ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250302739-A1 | LONG-ACTING INJECTABLE PHARMACEUTICAL COMPOSITIONS COMPRISING BIODEGRADABLE POLYMERS FOR DRUG DELIVERY | FORESEE PHARMACEUTICALS CO., LTD. (TW) | 2025-10-02 | — | — | US | claimed |
| EP-4618961-A1 | DEPOT COMPOSITIONS FOR VESICULAR MONOAMINE TRANSPORTER 2 (VMAT2) INHIBITORS | Foresee Pharmaceuticals Co., Ltd. (TW) | 2025-09-24 | — | — | EP | claimed |
| CN-118748939-A | Crystalline (+) -tetrabenazine | 逸达生物科技股份有限公司 | 2024-10-08 | — | — | CN | claimed |
| EP-4387593-A1 | POLYMER DEPOT COMPOSITIONS FOR SUSTAINED RELEASE DELIVERY OF VMAT2 INHIBITORS | Foresee Pharmaceuticals Co., Ltd. (TW) | 2024-06-26 | — | — | EP | claimed |
| WO-2024107925-A1 | DEPOT COMPOSITIONS FOR VESICULAR MONOAMINE TRANSPORTER 2 (VMAT2) INHIBITORS | FORESEE PHARMACEUTICALS CO., LTD. (TW) | 2024-05-23 | — | — | WO | claimed |
| US-20240156723-A1 | DEPOT COMPOSITIONS FOR VESICULAR MONOAMINE TRANSPORTER 2 (VMAT2) INHBITORS | FORESEE PHARMACEUTICALS CO., LTD. (TW) | 2024-05-16 | — | — | US | claimed |
| US-20230071314-A1 | POLYMERIC COMPOSITIONS FOR SUSTAINED DELIVERY OF VMAT2 INHIBITORS | FORESEE PHARMACEUTICALS CO., LTD. (TW) | 2023-03-09 | — | — | US | claimed |
| WO-2023023026-A1 | POLYMER DEPOT COMPOSITIONS FOR SUSTAINED RELEASE DELIVERY OF VMAT2 INHIBITORS | FORESEE PHARMACEUTICALS CO., LTD. (TW) | 2023-02-23 | — | — | WO | claimed |
| EP-4479051-A4 | CRYSTALLINE (+)-TETRABENAZINE | FORESEE PHARMACEUTICALS CO LTD (TW) | 2026-01-28 | — | — | EP | disclosed |
| US-20250302739-A1 | LONG-ACTING INJECTABLE PHARMACEUTICAL COMPOSITIONS COMPRISING BIODEGRADABLE POLYMERS FOR DRUG DELIVERY | FORESEE PHARMACEUTICALS CO., LTD. (TW) | 2025-10-02 | — | — | US | disclosed |
| EP-4618961-A1 | DEPOT COMPOSITIONS FOR VESICULAR MONOAMINE TRANSPORTER 2 (VMAT2) INHIBITORS | Foresee Pharmaceuticals Co., Ltd. (TW) | 2025-09-24 | — | — | EP | disclosed |
| US-20250163050-A1 | CRYSTALLINE (+)-TETRABENAZINE | FORESEE PHARMACEUTICALS CO., LTD. (TW) | 2025-05-22 | — | — | US | disclosed |
| US-20250163050-A1 | CRYSTALLINE (+)-TETRABENAZINE | FORESEE PHARMACEUTICALS CO., LTD. (TW) | 2025-05-22 | — | — | US | disclosed |
| EP-4479051-A1 | CRYSTALLINE (+)-TETRABENAZINE | Foresee Pharmaceuticals Co., Ltd. (TW) | 2024-12-25 | — | — | EP | disclosed |
| US-20230159528-A1 | VMAT2 INHIBITORS AND METHODS OF USE | NEUROCRINE BIOSCIENCES, INC. | 2023-05-25 | — | — | US | disclosed |
| US-20230071314-A1 | POLYMERIC COMPOSITIONS FOR SUSTAINED DELIVERY OF VMAT2 INHIBITORS | FORESEE PHARMACEUTICALS CO., LTD. (TW) | 2023-03-09 | — | — | US | disclosed |
| WO-2023023026-A1 | POLYMER DEPOT COMPOSITIONS FOR SUSTAINED RELEASE DELIVERY OF VMAT2 INHIBITORS | FORESEE PHARMACEUTICALS CO., LTD. (TW) | 2023-02-23 | — | — | WO | disclosed |
| US-20220127259-A1 | SOLID STATE FORMS OF VALBENAZINE | ASSIA CHEM IND LTD (IL) | 2022-04-28 | — | — | US | disclosed |
| US-11306082-B2 | Esters of dihydrotetrabenazine | FORESEE PHARMACEUTICALS CO., LTD. (TW) | 2022-04-19 | — | — | US | disclosed |
| US-11242341-B2 | Solid state forms of valbenazine | ASSIA CHEMICAL INDUSTRIES LTD. (IL) | 2022-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220127259-A1 | SOLID STATE FORMS OF VALBENAZINE | VARS1, CYP3A5, CYP3A4 | SLC18A2 221/4885KDM4E 1240/4885ABCB11 903/4885 |
| US-20250302739-A1 | LONG-ACTING INJECTABLE PHARMACEUTICAL COMPOSITIONS COMPRISING BIODEGRADABLE POLYMERS FOR DRUG DELIVERY | SLC6A3, SLC18A2, SLC6A2 | SLC18A2 2/4885KDM4E 2826/4885ABCB11 171/4885 |
| US-11306082-B2 | Esters of dihydrotetrabenazine | CD4, CD2, NFATC1 | SLC18A2 2337/4885KDM4E 869/4885ABCB11 1109/4885 |
| US-20250163050-A1 | CRYSTALLINE (+)-TETRABENAZINE | TTR, PYGB, HTT | SLC18A2 38/4885KDM4E 4813/4885ABCB11 1619/4885 |
| US-11242341-B2 | Solid state forms of valbenazine | VARS1, CYP3A5, CYP3A4 | SLC18A2 221/4885KDM4E 1240/4885ABCB11 903/4885 |
| US-20230159528-A1 | VMAT2 INHIBITORS AND METHODS OF USE | SLC18A2, SLC6A3, SLC6A2 | SLC18A2 1/4885KDM4E 1638/4885ABCB11 2490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.